Viridian Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- VOMVOA generated $24.7 million in net product revenue in its first quarter on the market, with more than 100 patients on therapy as of September 30th; management said the launch exceeded expectations.
- Management said the more than 100 patients had started treatment and completed at least one infusion, and that the revenue was driven by patient demand rather than inventory stocking.
- Viridian ended the quarter with just over $955 million in cash, cash equivalents, and marketable securities and said it could fund and execute its current business plans through profitability.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, ladies and gentlemen, and welcome to the Viridian Therapeutics conference call. At this time, participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. As a reminder, this conference call is being recorded. I will now hand the call over to Greg Rossino, Senior Director of Investor Relations at Viridian.
Please go ahead. Thank you, operator, and good morning, everyone.
Thank you for joining us to discuss Viridian's third quarter 2026 financial results and recent business updates. You can access the press release and the slides for today's call on the Investors page of our corporate website at viridiantherapeutics.com. Before we begin, I would like to remind everyone that today's call and webcast will contain forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. A description of these risks can be found in the forward-looking statement section disclaimer in the press release and slides issued today, as well as our SEC filings, including our quarterly report on Form 10-Q. With me today are Steve Mahoney, our President and Chief Executive Officer, Tony Casciano, our Chief Commercial Officer, and Seth Harmon, our Chief Financial Officer.
Shan Wu, our Chief Business Officer, will join us for Q&A. With that, I will turn the call over to Steve.
Thanks, Greg, and good morning, everyone. Thank you for joining us to discuss the results from our first quarter of LUMVOA launch in thyroid eye disease. As spelled out in our earnings release earlier this morning, it has been a very strong start, and the Viridian team has done another excellent job executing across the board. LUMVOA generated $24.7 million in net product revenue, and we had more than 100 patients on therapy as of September 30th. This is a very encouraging start to the launch and certainly has exceeded expectations. It is still early in the launch cycle, but we believe these results are a testament to LUMVOA's compelling product profile and the readiness and execution of our entire organization since day one of launch.
Before we provide more color on the Lumvoa launch, I want to highlight the emerging Viridian pipeline, which we believe will drive the next chapter of Viridian's growth in autoimmune disease. First, we're on track to submit our BLA for elegrobart in the first quarter of 2027. Ellie is our next-generation subcutaneous anti-IGF-1R. Based on our phase III results, Ellie has the potential to further improve the TED patient experience, and we believe that it will encourage more patients to seek treatment with at-home self-administration as infrequently as every eight weeks. Later this quarter, we also look forward to sharing first-in-human results for VRDN-008. 008 is a half-life extended FcRn inhibitor and is another example of a product candidate designed to reduce treatment burden with less frequent dosing while also providing sustained disease control.
We're also making strong progress with our anti-TSHR product candidate, now called VRDN-292, which we believe has the potential to be best in class. We expect to initiate a phase I clinical trial of VRDN-292 in Graves' patients later this quarter. Together, these programs represent the future for Viridian, building a leadership position in TED and expanding our portfolio across other autoimmune diseases. With that, I'll turn it over to Tony to walk through the Lumvoa launch.
Thanks, Steve, and good morning, everyone. It's been incredibly rewarding for our team to bring Lumvoa to patients with TED, and I'm proud of the start we've had. I'll start with a quick reminder of the market and Lumvoa's profile, and then walk through the quarter and where we go from here. Let's start with the patients. As a reminder, TED is an autoimmune condition that mostly affects women aged 40 to 50 with families, jobs, and active lives. TED causes inflammation, tissue expansion, and damage around the eyes. These cause disfiguring and debilitating symptoms that affect how patients function every day. The most severe cases can be sight-threatening. TED is also a large, established market where the first approved therapy generates roughly $2 billion in annual revenue, but represents roughly single-digit penetration of the overall TED market.
The TED prescriber base is highly concentrated, with roughly 2,000 core prescribers writing more than 80% of IGF-1R scripts. These physicians are experienced treating TED, they have established referral pathways, and they know how to coordinate with infusion centers. That allows us to reach the market efficiently with a focused field team. TED is a new start market. Every time a TED patient seeks treatment, there's an opportunity for Lumvoa to be chosen. That's where Lumvoa comes in. Lumvoa has a compelling product profile that we believe is aligned to unmet needs in TED. In our clinical trials, Lumvoa demonstrated robust improvements in both proptosis and diplopia for patients with both active and chronic TED. These improvements happened rapidly, with patients experiencing meaningful reductions in proptosis in as early as three weeks. We believe this combination of rapid, robust, and durable benefit is a compelling profile for TED patients.
Furthermore, LUMVOA delivers those benefits with a short 12-week course of therapy in just five infusions, allowing patients to complete treatment quickly and get back to their active lives. Early feedback is that this profile is resonating with patients and physicians, and that enthusiasm is already translating into meaningful launch momentum. With that backdrop, let's look at the quarter. As Steve said, the first quarter of LUMVOA launch exceeded expectations. We believe this strong start is driven by LUMVOA's compelling product profile, years of preparation, and strong execution by the Viridian team. When we announced LUMVOA approval, we discussed the early launch indicators we were focused on: field execution, payer coverage, and demand. We're making strong progress on all three in the early days of this launch.
We said at launch that our first priority would be rapidly engaging the core physicians who treat TED and prescribe IGF-1R, and we did just that. Our reps were fully trained and in the field talking to physicians about LUMVOA within 24 hours of approval. We have a highly experienced team with a track record across multiple launches, including buy-and-bill products. The relationships this team built ahead of approval with the core prescribers allowed us to hit the ground running and drive the broad engagement we've been able to secure with KOLs and prescribers. As expected, this team is executing at an extremely high level in the early stages of launch. Another top priority is market access. We said we would build on the foundation we established with payers during our pre-approval work to rapidly secure payer coverage post-approval, and we're doing exactly that.
In Q3, we completed post-approval presentations with all major payers. This represents more than 90% of covered lives in the U.S. We've made significant progress on our payer coverage and are on track to achieve broad coverage for LUMVOA on our estimated timeline of six to nine months from launch. We moved quickly to apply for a permanent J-code following approval and are pleased to announce that CMS has now assigned one for LUMVOA, which will become effective on January 1, 2027. Yet another example of the team being prepared and knowing how to navigate this market. This execution across the board, in conjunction with the compelling LUMVOA profile, is translating into strong early demand for LUMVOA. More than 100 patients were being treated with LUMVOA at the end of the quarter. To be clear, these aren't enrollment forms.
These are more than 100 patients who started treatment with LUMVOA and had completed at least one infusion by the end of the quarter. This demand drove $24.7 million in net product revenue for our first quarter of launch. We are extremely proud of this start and the strong execution across our stated launch priorities, but we also recognize it's still early and there's more work to do. The Viridian team is firing on all cylinders and focused on building on this momentum. Our launch priorities haven't changed. Drive awareness, differentiate LUMVOA, and deliver access. As we said at approval, in the early quarters, that means engaging prescribers, moving patients through the treatment journey, building coverage, and delivering great experiences through ViridianCares. That's where we're focused in the fourth quarter and beyond.
With prescribers, we're focused on continuing to educate on LUMVOA's clinical data and compelling profile and ensuring that they are fully supported by Viridian. We've already seen both breadth and depth in prescribing, and we will continue to focus on driving both. Our market access team has been successfully engaging with payers, both pre and post-launch, to drive policy coverage for LUMVOA and facilitate patient access. As we have stated, policy adoption takes time after product approval, and payers often have different timelines for decision-making. The team has made excellent progress on this front and will continue to expand from here. With respect to patients, ViridianCares, which is our patient support services team, continues to be critical to launch. ViridianCares has been focused on facilitating treatment initiation by supporting patients, physician offices, and infusion centers from enrollment throughout the treatment journey.
We are focused on continuing to provide great experiences for every patient and physician and on setting a standard for what they can expect from Viridian's world-class patient services, which is anchored by our experienced and extremely capable patient access liaison team. Overall, this was an exceptional first quarter of launch, and we couldn't be more proud with how the team is executing. That said, we know our work is just beginning, and there are many more patients with TED that we can help. We believe there's a significant long-term opportunity for LUMVOA, and we are 100% committed to continuing to deliver for patients. With that, I'll turn it over to Seth.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
21 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
